Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is a financially stable company that has shown significant growth and success, with a diverse and growing customer base due to their cutting-edge AI-driven genomics platform. Their recent partnerships and planned applications could drive further revenue and market expansion. With a strong presence in multiple countries and a recurring revenue model, SOPHiA is in a good position to achieve profitability and continue to grow in the rapidly evolving field of data-driven medicine.

Bears say

Sophia Genetics is a data-driven healthcare technology company that offers cloud-based diagnostic analysis solutions for life sciences research and patient care. While the company has a global presence and impressive partnerships with prestigious cancer centers, there are concerns surrounding their ability to scale sales and marketing cost-effectively, sustain and grow customer relationships, and effectively penetrate global markets with diverse data. Additionally, the company is not yet profitable, and there is uncertainty about if and when they will achieve profitability. While the company's innovative platform and partnerships are notable, they do face competition from centralized testing providers and platform players.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.